All Categories
Refine Search
ETC-159
Novel inhibitor of PORCN, inhibiting ß-catenin reporter activity in a dose-dependent manner and being highly efficacious in molecularly defined colorectal cancers (CRCs) with R-spondin translocations
Ethosuximide
The first choice drug for treating absence seizures in part because it lacks the idiosyncratic hepatotoxicity of the alternative anti-absence drug, valproic acid
